| Literature DB >> 32899626 |
Seyed Alireza Salami1, Federico Martinelli2, Antonio Giovino3, Ava Bachari4, Neda Arad5, Nitin Mantri4.
Abstract
Cannabis is an annual plant with a long history of use as food, feed, fiber, oil, medicine, and narcotics. Despite realizing its true value, it has not yet found its true place. Cannabis has had a long history with many ups and downs, and now it is our turn to promote it. Cannabis contains approximately 600 identified and many yet unidentified potentially useful compounds. Cannabinoids, phenolic compounds, terpenoids, and alkaloids are some of the secondary metabolites present in cannabis. However, among a plethora of unique chemical compounds found in this plant, the most important ones are phytocannabinoids (PCs). Over hundreds of 21-22-carbon compounds exclusively produce in cannabis glandular hairs through either polyketide and or deoxyxylulose phosphate/methylerythritol phosphate (DOXP/MEP) pathways. Trans-Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are those that first come to mind while talking about cannabis. Nevertheless, despite the low concentration, cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabinodiol (CBND), and cannabinidiol (CBDL) may have potentially some medical effects. PCs and endocannabinoids (ECs) mediate their effects mainly through CB1 and CB2 receptors. Despite all concerns regarding cannabis, nobody can ignore the use of cannabinoids as promising tonic, analgesic, antipyretic, antiemetic, anti-inflammatory, anti-epileptic, anticancer agents, which are effective for pain relief, depression, anxiety, sleep disorders, nausea and vomiting, multiple sclerosis, cardiovascular disorders, and appetite stimulation. The scientific community and public society have now increasingly accepted cannabis specifically hemp as much more than a recreational drug. There are growing demands for cannabinoids, mainly CBD, with many diverse therapeutic and nutritional properties in veterinary or human medicine. The main objective of this review article is to historically summarize findings concerning cannabinoids, mainly THC and CBD, towards putting these valuable compounds into food, feed and health baskets and current and future trends in the consumption of products derived from cannabis.Entities:
Keywords: CBD oil; CNS; PNS; gene networks; hemp; medcannabase; phytocannabinoids; receptors
Mesh:
Substances:
Year: 2020 PMID: 32899626 PMCID: PMC7571138 DOI: 10.3390/molecules25184036
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Natural important cannabinoids and their structure.
Figure 2Cannabinoids receptors CB1 and CB2 and their natural distribution in the human body.
Figure 3The phytocannabinoids biosynthesis pathway in cannabis and its related gene networks [12]. Heating will immediately decarboxylate THCA and CBDA into THC and CBD making them readily available for use by your body.
Pharmacological and therapeutic effects of endocannabinoids and phytocannabinoids.
| Effects | THC | AEA | 2-AG | CBD | CBC | CBDV | CBG | THCV | References |
|---|---|---|---|---|---|---|---|---|---|
| Suppress Seizure | √ | [ | |||||||
| Reduce Parkinson’s Disease symptoms | √ | [ | |||||||
| Anti-inflammatory | √ | √ | √ | √ | √ | √ | √ | [ | |
| Reduce weight | √ | [ | |||||||
| Anticonvulsant | √ | [ | |||||||
| Anxiolytic | √ | [ | |||||||
| Effective against cancer | √ | √ | √ | √ | √ | [ | |||
| Chemotherapy induced emesis | √ | √ | [ | ||||||
| Effective against glaucoma | √ | √ | √ | [ | |||||
| Epilepsy | √ | √ | [ | ||||||
| Oxidative injury | √ | [ | |||||||
| Schizophrenia | √ | √ | [ | ||||||
| Neuro-degeneration | √ | [ | |||||||
| Diabetic retinopathy | √ | [ | |||||||
| Colitis | √ | [ | |||||||
| Exhibits Neuron protection | √ | [ | |||||||
| Antiemetic, Analgesic activity | √ | √ | [ | ||||||
| Energy and fat metabolism | √ | √ | [ | ||||||
| Insulin sensitivity | √ | √ | [ | ||||||
| Anorexia | √ | [ | |||||||
| Bowel disease | √ | [ |
Summaries of different forms of cannabinoids available on the world market or under development and clinical trials.
| Product | Possible Therapeutic Effects | Component | References |
|---|---|---|---|
| Bedrocan® |
Spasms associated with pain in MS Myelon damage Improvement of radiation-induced nausea and vomiting HIV medication and anorexia Chronic neurological pain Treatment of Gilles de la Tourette syndrome palliative/supportive care | (>22% Δ9-THC and <1% CBD) | [ |
| Bedrobinol® |
Treatment of spasticity associated pain in MS The improvement of radiation-induced nausea and vomiting associated with cancers, radiation therapy and HIV therapy Chronic pain conditions especially neuropathic pain, cachexia, anorexia in patients with cancer, AIDS, and anorexia nervosa | 13% Δ9-THC and 1% CBD | [ |
| Marinol® |
Treating anorexia associated with weight loss in HIV/AIDS Treating nausea and vomiting related to chemotherapy in patients with cancer especially for those patients who do not respond to other medicines | Dronabinol in doses 2.5, 5, and 10 mg | [ |
| Namisol® |
improve abdominal pain resulting from chronic pancreatitis (CP) | Purified Δ9-THC (>98%) | [ |
| Cesamet™ |
Treatment of nausea and vomiting caused by cancer chemotherapy Effective in chronic noncancer pain [ | THC in the form of oral capsules which contain 1 mg (2.7 µmol) nabilone | [ |
| Sativex® |
To relieve muscle stiffness and neuropathic pain and sleep disturbances in MS patients | Nabiximols contains 2.7 mg of Δ9-THC and 2.5 mg of CBD in a 1:1 ratio. Sativex® | [ |
| Epidiolex® |
To treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome | Purified pharmaceutical grade cannabidiol (CBD), | [ |